Eric Bauer - Repro Med COO
COO
Mr. Eric Bauer is a Chief Operating Officer of the company. He has more than 25 years of executive management experience in a variety of manufacturing and FDA regulated industries. Prior to joining RMS Medical Products, Mr. Bauer was Chief Executive Officer of 2020Value, LLC, a consulting and coaching business, from 2015 to 2017. He assisted clients with maximizing longterm sustainable value by focusing on people, processes and products. He established operational excellence supported through strategic initiatives to bring significant EBITDA growth with highly efficient teams for client organizations. From 2011 to 2015, Mr. Bauer served in the role of Chief Executive Officer for KAKO Beauty Products, consisting of the development of prestige skin care goods together with designing, packaging, marketing and implementation of a channel distribution strategy. From 2008 to 2011, Mr. Bauer was Chief Executive Officer of Chemaid Laboratories, a Private Equityowned contract manufacturing company providing high quality skin care, haircare, fragrance and bath products to the prestige cosmetics industry. At Chemaid, Mr. Bauer implemented innovations with the highest quality approach. With PL responsibility, he presided over the Company instilling his strategic vision, maximizing longterm shareholder value, which doubled revenue growth with a significant increase in EBITDA and pioneered cultural change in the Company. since 2017.
| Age | 59 |
| Tenure | 7 years |
| Phone | 845-469-2042 |
| Web | http://www.rmsmedicalproducts.com |
Repro Med Management Efficiency
The company has return on total asset (ROA) of 10.67 % which means that it generated a profit of $10.67 on every $100 spent on assets. This is normal as compared to the sector avarege. Similarly, it shows a return on stockholder's equity (ROE) of 0.27 %, meaning that it created $0.27 on every $100 dollars invested by stockholders. Repro Med's management efficiency ratios could be used to measure how well Repro Med manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 444.08 K in liabilities with Debt to Equity (D/E) ratio of 4.6, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Repro Med Systems has a current ratio of 5.19, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Repro Med until it has trouble settling it off, either with new capital or with free cash flow. So, Repro Med's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Repro Med Systems sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Repro to invest in growth at high rates of return. When we think about Repro Med's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 3 records | COO Age | ||
| Michael Wilkins | United Fire Group | 54 | |
| David McMillan | QBE Insurance Group | 52 | |
| Julie Stephenson | United Fire Group | 56 | |
Management Performance
| Return On Equity | 0.27 | |||
| Return On Asset | 10.67 |
Repro Med Systems Leadership Team
Elected by the shareholders, the Repro Med's board of directors comprises two types of representatives: Repro Med inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Repro. The board's role is to monitor Repro Med's management team and ensure that shareholders' interests are well served. Repro Med's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Repro Med's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Karen Fisher, CFO and Treasurer | ||
| Robert Allen, Director | ||
| Andrew Sealfon, Co-Founder, Chairman, CEO and President and Head of RandD | ||
| David Anderson, Director | ||
| Donald Pettigrew, President and Chief Commercial Officer | ||
| Manuel Marques, COO | ||
| Fred Ma, Principal Executive Officer | ||
| Mark Pastreich, Director | ||
| Daniel Goldberger, Independent Director | ||
| Cyril Narishkin, Interim COO and Additional Director | ||
| John Fletcher, Independent Director | ||
| Paul Baker, Director | ||
| James Beck, Director | ||
| Brad Sealfon, Marketing Manager and Director | ||
| Eric Bauer, COO | ||
| Arthur Radin, Director | ||
| Joseph Manko, Additional Director |
Repro Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Repro Med a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.27 | |||
| Return On Asset | 10.67 | |||
| Profit Margin | 0.13 % | |||
| Operating Margin | 9.81 % | |||
| Current Valuation | 131.75 M | |||
| Shares Outstanding | 38.38 M | |||
| Shares Owned By Insiders | 44.43 % | |||
| Shares Owned By Institutions | 17.96 % | |||
| Price To Earning | 393.75 X | |||
| Price To Book | 16.13 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Repro Med in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Repro Med's short interest history, or implied volatility extrapolated from Repro Med options trading.
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Other Consideration for investing in Repro OTC Stock
If you are still planning to invest in Repro Med Systems check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Repro Med's history and understand the potential risks before investing.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |